\* Patrick T. PRENDERGAST

Art Unit: 1642

\* Assigned 6-10-02

**PATENT** 

ctitioner's ocket No.: 802 003

In re the application of:

Ser. No.: 10/091,855

Filed: March 6, 2002

Confirmation No.: 8597

COMBINATION THERAPY FOR REDUCTION OF TOXICITY OF

CHEMOTHERAPEUTIC AGENTS

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on June 6, 2002 under "EXPRESS MAIL"

mailing label number EV 01907 2049 US

**Assistant Commissioner for Patents** Washington, DC 20231

## INFORMATION DISCLOSURE STATEMENT.

Sir:

For:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. Copies of each of the references listed on Form PTO-1449 are attached.

WO 99/01118 discloses a method to enhance cytotoxic activity of an antineoplastic drug with an antioxidant and discloses inhibitors of lipoxygenases among a group of antioxidants and discloses Gencitabine among a group of antineoplastic agents.

The above information is presented so that the Patent and Trademark Office may, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that these references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The Constant is hereby authorized to charge any additional fees associated wit

this communication or credit any overpayment to Deposit Account No. 50-1446.

Respectfully submitted,

June 6, 2002

JUN 0 6 2002 X

Date

Kevin C. Brown

Reg. No. 32,402

KCB/jms

BURR & BROWN P.O. Box 7068

Syracuse, NY 13261-7068

Customer No.: 025191

Telephone: (315) 233-8300 Facsimile: (315) 233-8320

|   |                 |                 | IPA                     | • '                  |                        |     |         |        |
|---|-----------------|-----------------|-------------------------|----------------------|------------------------|-----|---------|--------|
| Form PTO-                                       | 1449            | 7               | 50                      |                      | Complete if Known      | 귞   |         | $\Box$ |
|   | ENT OF COMMERCE |                 | ا 0 6 2002 کا ا<br>پیرا | Application Number   | 10/091,855             | 오   |         | m      |
| INTOR   |                 | A LEE           |                         | Filing Date          | March 6, 2002          | 贸   | SN      | C      |
| INFORMATION DISCLOSURDED STATEMENT BY APPLICANT |                 |                 | ANT                     | First Named Inventor | Patrick T. PRENDERGAST | 豆   | <u></u> | Ш      |
| SIAIL   | MATERIAL DI     | ATTLIC          | AIVI                    | Art Unit             | 1642                   | 16  | 22      | $\leq$ |
|   |                 | 4               | 1                       | Examiner Name        | Not Assigned           | 200 | 02      | 111    |
|   | (use as many sh | eeis as necessa |                         | Confirmation No.     | 8597                   | 8   |         |        |
| Sheet   | 1               | of              | 1                       | Attorney Docket No.  | 802_003                |     |         |        |

## **U.S. PATENT DOCUMENTS**

| Exam.<br>Initial |    | Document Number | Date       | Name           | Class | Sub<br>Class | Filing Date |
|------------------|----|-----------------|------------|----------------|-------|--------------|-------------|
|                  | AA | 6,136,839       | 10/24/2000 | Isakson et al. |       |              |             |

## **FOREIGN PATENT DOCUMENTS**

|        | Document Number | Date      | Country | Class | Sub<br>Class | Translation | Abstract |
|--------|-----------------|-----------|---------|-------|--------------|-------------|----------|
| <br>AB | 99/01118        | 1/14/1999 | wo      |       |              |             |          |
| AC     | 00/38730        | 07/6/2000 | WO      |       |              |             |          |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages etc.)

| AD | E. H. Mustafa, M. Abu Zarga, S. Abdalla, "Effects of Cirsiliol, a Flavone Isolated from Achillea Fragrantissima, on Rat Isolated Ileum", General Pharmacology, Vol. 23 (1992); No. 3, pp. 555-560, ISSN: 0306-3623   |
|----|--|
| AE | Ichitomo Miwa, Jun Okuda, Tokunaru Horie, Mitsuru Nakayama, "Inhibition of Intestinal α-Glucosidases and Sugar Absorption by Flavones", <u>Chem. Pharm. Bull.</u> , Vol. 34 (1986), No. 2, pp. 838-844   |
| AF | Jun Okuda, Ichitomo Miwa, Kazuhiro Inagaki, Tokunaru Horie, Mitsuru Nakayama, "Inhibition of Aldose Reductases from Rat and Bovine Lenses by Flavonoids", Biochem Pharmacol, Vol. 31 (1982), No. 23, pp. 3807-3822   |
| AG | P. Lissoni, S. Barni, M. Mandalá, A. Ardizzoia, F. Paolorossi, M. Vaghi, R. Longarini, F. Malugani and G. Tancini, "Decreased Toxicity and Increased Efficacy of Cancer Chemotherapy Using the Pineal Hormone Melatonin in Metastatic Solid Tumour Patientswith Poor Clinical Status", <u>European Journal of Cancer</u> , Vol. 35 (1999), No. 12, pp. 1688-1692 |
| АН | M. L. Ferrándiz, M. J. Alcaraz, "Anti-Inflammatory Activity and Inhibition of Arachidonic Acid Metabolism by Flavonoids", Agents and Actions, Vol. 32, 3/4 (1991), pp. 283-288   |
| AI | Tanihiro Yoshimoto, Masayuki Furukawa, Shozo Yamamoto, Tokunaru Horie, Shigekatsu Watanabe-Kohno, "Flavonoids: Potent Inhibitors of Arachidonate 5-Lipoxygenase", <u>Biochemical and Biophysical Research Communications</u> , Vol. 116 (1983), No. 2, pp. 612-618   |
| AJ | Peng Huang and William Plunkett, "Induction of Apoptosis by Gemcitabine", Seminars in Oncology, Vol. 22 (1995), No. 4, Suppl 11, pp. 19-25   |

| •  |  |
|----|--|
|    | OTHER DOCUMENTS (Cont'd)  (Instading Author, Title, Date, Pertinent Pages etc.)  |
| AK | Ariel F. Sorland Bara Helfrich, Daniel C. Chan, Lynn E. Heasley, Paul A. Bunn, Jr., Ting-Chao Chou, — "Synergistic Effects of New Chemopreventive Agents and Conventional Cytotoxic Agents against Burnan Bung Cancer Cell Lines", Cancer Research, Vol. 59 (December 1999), pp. 6178-6184   |
| AL | Shinji Funayama, Kanki Komiyama, Yukinori Miyaichi, Tsuyoshi Tomimori, Shigeo Nozoe, "Cytockal and Antimicrobial Activities of Flavonoids", Natural Medicines, Vol. 49(1995), No. 3, pp. 322-328   |
| АМ | Tetsuya Tsukada, Kunio Nakashima, Shigeru Shirakawa, "Arachidonate 5-Lipoxygenase Inhibitors Show Potent Antiproliferative Effects on Human Leukemia Cell Lines", <u>Biochemical and Biophysical Research Communications</u> , Vol. 140 (1986), No. 3, pp. 832-836   |
| AN | J.E. Harris, W.A. Alrefai, J. Meng, K.M. Anderson, "Five-Lipoxygenase Inhibitors Reduce PANC-1 Survival: Synergism of MK886 with Gamma Linolenic Acid", <u>Eicosanoids and Other Bioactive Lipids in Cancer</u> , <u>Inflammation</u> , and <u>Radiation Injury</u> , 4, Edited by Honn et al., Kluwer Academic/Plenum Publishers, New York, 1999, pp. 505-510           |
| AO | Henric Blomgren and Gunilla Kling-Andersson, "Growth Inhibition of Human Malignant Glioma Cells in Vitro by Agents which Interfere with Biosynthesis of Eicosanoids", <u>Anticancer Research</u> , Vol. 12, pp. 981-986 (1992)   |
| AP | K. M. Anderson, T. Seed, J. Meng, D. Ou, W.A. Alrefai, J.E. Harris, "Five-Lipoxygenase Inhibitors Reduce PANC-1 Survival: The Mode of Cell Death and Synergism of MK 886 with Gamma Linolenic Acid", Anticancer Research, Vol. 18, pp. 791-800 (1998)  |
| AQ | Michele T. Yip-Schneider, Christopher J. Sweeney, Sin-Ho Jung, Pamela L. Crowell and Mark S. Marshall, "Cell Cycle Effects of Nonsteroidal Anti-Inflammatory Drugs and Enhanced Growth Inhibition in Combination with Gemcitabine in Pancreatic Carcinoma Cells", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , Vol. 298 (2001), No. 3, pp. 976-985 |

| l         |                  |   |
|-----------|------------------|---|
| Examiner: | Date Considered: | 1 |
|           | Date Constacted. |   |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.